Contemporary management of postchemotherapy testis cancer

European Urology

Volumn 62, Issue 5, 2012, Pages 867-876

  Daneshmand, Siamak ^a   Albers, Peter ^b   Fosså, Sophie Dorothea ^c   Heidenreich, Axel ^d   Kollmannsberger, Christian ^e   Krege, Susan ^f   Nichols, Craig ^g   Oldenburg, Jan ^h   Wood, Lori ⁱ  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Krankenhaus Maria Hilf   (Germany)

^g VIRGINIA MASON MEDICAL CENTER   (United States)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Chemotherapy; complications; Follow up; Germ cell tumor; Retroperitoneal lymph node dissection; Testis cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; DISSEMINATED CANCER; DRUG MEGADOSE; FOLLOW UP; GERM CELL TUMOR; HUMAN; LAPAROSCOPIC SURGERY; LYMPH NODE DISSECTION; MEDLINE; PARAAORTIC LYMPH NODE; PATIENT CARE; PRIORITY JOURNAL; RETROPERITONEAL DISEASE; REVIEW; SALVAGE THERAPY; SEMINOMA; STEM CELL TRANSPLANTATION; TERATOMA; TESTIS CANCER; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; LAPAROSCOPY; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; NEOPLASMS, GERM CELL AND EMBRYONAL; RETROPERITONEAL SPACE; TESTICULAR NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84867075204     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.08.014     Document Type: Review

References (73)

1. J.F. Sturgeon, M.J. Moore, and D.M. Kakiashvili Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors:the Princess Margaret Hospital's experience Eur Urol 59 2011 556 562
2. C. Kollmannsberger, C. Moore, and K.N. Chi Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy Ann Oncol 21 2010 1296 1301
3. C. Kollmannsberger, S. Tyldesley, and C. Moore Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies Ann Oncol 22 2011 808 814
4. S. Daneshmand, H. Djaladat, and C. Nichols Management of residual mass in nonseminomatous germ cell tumors following chemotherapy Ther Adv Urol 3 2011 163 171
5. A.C. Pfannenberg, K. Oechsle, and C. Bokemeyer The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors - prospects for management World J Urol 22 2004 132 139
6. M. Bachner, Y. Loriot, and M. Gross-Goupil 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial Ann Oncol 23 2012 59 64
7. M. De Santis, A. Becherer, and C. Bokemeyer 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial J Clin Oncol 22 2004 1034 1039
8. L. Wood, C. Kollmannsberger, and M. Jewett Canadian consensus guidelines for the management of testicular germ cell cancer Can Urol Assoc J 4 2010 e19 e38
9. P. Albers, W. Albrecht, and F. Algaba EAU guidelines on testicular cancer: 2011 update Eur Urol 60 2011 304 319
10. J. Sheinfeld, G. Bartsch, and G. Bosl Campbell-Walsh urology 2007 WB Saunders Philadelphia, PA
11. E.P. Fox, T.D. Weathers, and S.D. Williams Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections J Clin Oncol 11 1993 1294 1299
12. K. Fizazi, S. Tjulandin, and R. Salvioni Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group J Clin Oncol 19 2001 2647 2657
13. G.C. Toner, D.M. Panicek, and R.T. Heelan Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection J Clin Oncol 8 1990 1683 1694
14. E.W. Steyerberg, H.J. Keizer, and S.D. Fossa Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups J Clin Oncol 13 1995 1177 1187
15. E.W. Steyerberg, A. Gerl, and S.D. Fossa Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer J Clin Oncol 16 1998 269 274
16. Y. Vergouwe, E.W. Steyerberg, and R.S. Foster Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients Eur Urol 51 2007 424 432
17. E.W. Steyerberg, H.J. Keizer, and D.T. Sleijfer Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy Radiology 215 2000 437 444
18. P. Albers, L. Weissbach, and S. Krege Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group J Urol 171 2004 1835 1838
19. C. Kollmannsberger, S. Daneshmand, and A. So Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery J Clin Oncol 28 2010 537 542
20. Y. Ehrlich, M.J. Brames, and S.D. Beck Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28 2010 531 536
21. T. Tarin, B. Carver, and J. Sheinfeld The role of lymphadenectomy for testicular cancer: indications, controversies, and complications Urol Clin North Am 38 2011 439 449
22. S.D. Fossa, S. Ous, H.H. Lien, and A.E. Stenwig Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer J Urol 141 1989 557 559
23. J. Oldenburg, G.C. Alfsen, and H.H. Lien Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses J Clin Oncol 21 2003 3310 3317
24. S. Krege, J. Beyer, and R. Souchon European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG) I. Eur Urol 53 2008 478 496
25. DA-CL Kakiashvili, and M. Moore Post-chemotherapy retroperitoneal lymph node dissection for testicular germ cell tumors: is surgery indicated in all patients and is bilateral template necessary? Princess Margaret Hospital experience [abstract] J Urol 181 Suppl 2009 325
26. S. Daneshmand, A.J. Stephenson, J. Sheinfeld, and M.A. Jewett The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation Urol Oncol 29 2011 842 847
27. B.S. Carver, B. Shayegan, and S. Eggener Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection J Clin Oncol 25 2007 4365 4369
28. D.P. Wood Jr., H.W. Herr, and G. Heller Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors J Urol 148 1992 1812 1815 discussion 1815-6
29. F. Rabbani, S.L. Goldenberg, and M.E. Gleave Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? Br J Urol 81 1998 295 300
30. A. Heidenreich, D. Pfister, and R. Witthuhn Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection Eur Urol 55 2009 217 226
31. S.D. Beck, R.S. Foster, and R. Bihrle Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer 110 2007 1235 1240
32. A.G. Aprikian, H.W. Herr, D.F. Bajorin, and G.J. Bosl Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors Cancer 74 1994 1329 1334
33. P.C. Brenner, H.W. Herr, and M.J. Morse Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis J Clin Oncol 14 1996 1765 1769
34. M.S. McGuire, F. Rabbani, and H. Mohseni The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours BJU Int 91 2003 469 473
35. B. Besse, D. Grunenwald, and A. Flechon Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis J Thorac Cardiovasc Surg 137 2009 448 452
36. N.E. Jacobsen, S.D. Beck, and L.E. Jacobson Is retroperitoneal histology predictive of liver histology at concurrent post-chemotherapy retroperitoneal lymph node dissection and hepatic resection? J Urol 184 2010 949 953
37. J.J. Rassweiler, O. Seemann, and T.O. Henkel Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations J Urol 156 1996 1108 1113
38. M.A. Palese, L.M. Su, and L.R. Kavoussi Laparoscopic retroperitoneal lymph node dissection after chemotherapy Urology 60 2002 130 134
39. P. Albers Surgery in testis cancer: laparoscopic and open techniques Curr Opin Urol 12 2002 435 440
40. J.P. Calestroupat, R. Sanchez-Salas, and X. Cathelineau Postchemotherapy laparoscopic retroperitoneal lymph node dissection in nonseminomatous germ-cell tumor J Endourol 23 2009 645 650
41. A.J. Stephenson, R. Tal, and J. Sheinfeld Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer J Urol 176 2006 1996 1999 discussion 1999
42. C. Winter, D. Pfister, and J. Busch Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group Eur Urol 61 2012 403 409
43. B.S. Carver, and J. Sheinfeld Management of post-chemotherapy extra-retroperitoneal residual masses World J Urol 27 2009 489 492
44. B. Duty, and S. Daneshmand Resection of the inferior vena cava without reconstruction for urologic malignancies Urology 74 2009 1257 1262
45. P.E. Spiess, W. Kassouf, and G.A. Brown Surgical management of growing teratoma syndrome: the M. D. Anderson Cancer Center experience J Urol 177 2007 1330 1334 discussion 1334
46. A.A. Mosharafa, R.S. Foster, and M.O. Koch Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer J Urol 171 2004 1839 1841
47. C. Winter, J.D. Raman, J. Sheinfeld, and P. Albers Retroperitoneal lymph node dissection after chemotherapy BJU Int 104 2009 1404 1412
48. J.A. Pettus, B.S. Carver, and T. Masterson Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer Urology 73 2009 328 331 discussion 331-2
49. E.A. Ronnen, G.V. Kondagunta, and J. Bacik Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy J Clin Oncol 23 2005 6999 7004
50. J. Oldenburg, J.M. Martin, and S.D. Fossa Late relapses of germ cell malignancies: incidence, management, and prognosis J Clin Oncol 24 2006 5503 5511
51. N.J. van As, D.C. Gilbert, and J. Money-Kyrle Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse Br J Cancer 98 2008 1894 1902
52. National Comprehensive Cancer Network (NCCN) testicular cancer guidelines. National Comprehensive Cancer Network Web site. http://www.nccn.org/ professionals/physician%C2%AC-gls/pdf/testicular.pdf.
53. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer. European Association of Urology. Web site. http://www.uroweb.org/gls/pdf/10- testicular-cancer.pdf.
54. H.J. Schmoll, K. Jordan, and R. Huddart Testicular non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl 5 2010 v147 v154
55. S.D. Beck, R.S. Foster, and R. Bihrle Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection J Clin Oncol 23 2005 6149 6156
56. T.A. Ong, M.H. Winkler, and P.M. Savage Retroperitoneal lymph node dissection after chemotherapy in patients with elevated tumour markers: indications, histopathology and outcome BJU Int 102 2008 198 202
57. S.D. Beck, R.S. Foster, and R. Bihrle Post chemotherapy RPLND in patients with elevated markers: current concepts and clinical outcome Urol Clin North Am 34 2007 219 225 abstract ix-x
58. R.T. Zon, C. Nichols, and L.H. Einhorn Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels J Clin Oncol 16 1998 1294 1297
59. A. Lorch, C. Bascoul-Mollevi, and A. Kramar Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database J Clin Oncol 29 2011 2178 2184
60. L.H. Einhorn, S.D. Williams, and A. Chamness High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors N Engl J Med 357 2007 340 348
61. D.R. Feldman, J. Sheinfeld, and D.F. Bajorin TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis J Clin Oncol 28 2010 1706 1713
62. G.V. Kondagunta, J. Bacik, and A. Donadio Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors J Clin Oncol 23 2005 6549 6555
63. S.D. Beck, R.S. Foster, and R. Bihrle Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer Urol Oncol 23 2005 423 430
64. A. Heidenreich, D. Thuer, and S. Polyakov Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis Eur Urol 53 2008 260 274
65. A.A. Mosharafa, R.S. Foster, and B.C. Leibovich Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol 169 2003 2126 2128
66. J. Oldenburg, G.C. Alfsen, H. Waehre, and S.D. Fossa Late recurrences of germ cell malignancies: a population-based experience over three decades Br J Cancer 94 2006 820 827
67. D.S. Sharp, B.S. Carver, and S.E. Eggener Clinical outcome and predictors of survival in late relapse of germ cell tumor J Clin Oncol 26 2008 5524 5529
68. M.F. Lutke Holzik, H.J. Hoekstra, and N.H. Mulder Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor Ann Surg Oncol 10 2003 131 135
69. A.W. van den Belt-Dusebout, R. de Wit, and J.A. Gietema Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer J Clin Oncol 25 2007 4370 4378
70. U.B. Chaudhary, and J.R. Haldas Long-term complications of chemotherapy for germ cell tumours Drugs 63 2003 1565 1577
71. R. Abouassaly, S.D. Fossa, and A. Giwercman Sequelae of treatment in long-term survivors of testis cancer Eur Urol 60 2011 516 526
72. L.B. Travis, S.D. Fossa, and S.J. Schonfeld Second cancers among 40,576 testicular cancer patients: focus on long-term survivors J Natl Cancer Inst 97 2005 1354 1365
73. L.B. Travis, C. Beard, and J.M. Allan Testicular cancer survivorship: research strategies and recommendations J Natl Cancer Inst 102 2010 1114 1130